Welcome to Allgens Biotek, Inc.™
Allgens Biotek, Inc.™ develops and manufactures innovative platforms of biomimetic synthetic bone grafts for use in regions of compromised cancellous and cortical bone. These products are used in many different skeletal applications in and around the human skeleton. Allgens Biotek manufactures both OEM and proprietary brands, and markets and distributes them globally. Some of our proprietary brands include the Bongold™ family of products.
Allgens’s mission is to become a worldwide leader in regenerative synthetic products that provide solutions for patients, surgeons and hospitals. Allgens invests heavily in research and development to pave the way for the next generation of biologics and bio-active regenerative products. We are working diligently to push the boundaries of anatomy saving surgical procedures today and into the future.
Allgens Biotek, Inc is the US-based subsidiary of Allgens Medical Science and Technology Co, Ltd, based in Beijing, China. The parent company was founded in 2004 by a leading Chinese professor, Dr. Fuzhai Cui, from Tsinghua University, in Beijing, China. His original research was awarded the highest national level technology advancement awarded by the Chinese government in 2011 and 2012. Original funding for the company came through the Chinese government with the most recent funding round provided by a group of private equity investors whose goal is to introduce Allgens’s innovative synthetic biomimetic bone graft portfolio on the world stage.
Allgens Biotek, Inc.™ is a leading medical device company focused on developing visionary innovative technologies and platforms closely aligned to natural bone structures and compositions that can be used in a wide range of surgical applications, including: orthopedic, spinal, craniofacial and dental applications.
Allgens Biotek, Inc.™ seeks to become a worldwide leader in regenerative synthetic products that provide solutions for patients, surgeons, and hospitals.
Allgens Biotek products are developed to improve surgical outcome for surgeons and patients throughout the entire bone healing process. Our products closely mirror real bone structure and composition while providing a number of benefits to surgeons and patients including excellent moldability characteristics, superior handling properties that coincide with best-in-class clinical performance. Our synthetic biomimetic bone graft product platform degrades as new bone regeneration progress, synchronizing a natural bone remodeling and regeneration process.